LUGANO, Switzerland • May 31th, 2022 • Cerbios-Pharma SA announces the opening, at its Lugano site, of an additional R&D laboratory unit equipped with state-of-the-art technologies.
This new space will host an area for the development activities related to Highly Potent Molecules and a separate section for the analytical support of CDMO projects. These laboratories, designed to ensure operators safety, allow Cerbios to increase by 50% the R&D capabilities for HPAPIs chemical development and to double the R&D analytical services for biotech and chemical products, making the management of CDMO projects more efficient and faster. In parallel, Cerbios created a new analytical R&D group dedicated to handling all the analytical activities from the development up to phase I/II, including capabilities for cGMP analytical services.
This investment reinforces the long-term strategy of Cerbios for HPAPIs and its approach for continuous improvement, being aware of the increasing complexity of High Potent molecules and the importance of the analytical activities in the scope of HPAPIs and Antibody-Drug Conjugates (ADCs) projects.
